Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals, Inc. (ELDN)
:ELDN
ELDN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.00 - $5.54
Previous CloseN/A
Volume121.23K
Average Volume (3M)238.71K
Market Cap
$194.02M
Enterprise Value$107.11M
Total Cash (Recent Filing)$31.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
May 08, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding59,881,775
10 Day Avg. Volume170,240
30 Day Avg. Volume238,709
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.53
Forecast
1Y Price Target
$10.40Price Target Upside220.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Eledon Pharmaceuticals News
PremiumCompany Announcements
Eledon Pharmaceuticals Reports 2024 Financial Results and Clinical Advances
PremiumCompany Announcements
Eledon Pharma Adjusts CEO Bonus Structure---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsELDN completed enrollment in BESTOW ~4 months ahead of schedule, suggesting an encouraging physician and patient experience.
Market PotentialThe potential for tegoprubart to help people with Type 1 diabetes achieve durable insulin independence has blockbuster drug implications.
Product EfficacyRecent data from the trial evaluating tego as part of an immunosuppressive regimen to prevent islet-cell-transplant rejection appear compelling, with subjects achieving significant insulin independence.
Bears Say
Clinical DataData from the first 13 participants in the open-label Phase Ib study continue to suggest that tegoprubart offers a favorable alternative to CNIs in the prevention of kidney transplant rejection.
Competitive LandscapeThe kidney transplantation market is a large and growing one, with a significant unmet need for novel immunosuppressants that can prevent graft rejection, but also avoid the common side effects associated with current immunosuppressants.
---
Ownership Overview
22.43% Insiders
5.53% Mutual Funds
0.04% Other Institutional Investors
66.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELDN FAQ
What was Eledon Pharmaceuticals, Inc.’s price range in the past 12 months?
Eledon Pharmaceuticals, Inc. lowest stock price was $2.00 and its highest was $5.54 in the past 12 months.
What is Eledon Pharmaceuticals, Inc.’s market cap?
Eledon Pharmaceuticals, Inc.’s market cap is $194.02M.
When is Eledon Pharmaceuticals, Inc.’s upcoming earnings report date?
Eledon Pharmaceuticals, Inc.’s upcoming earnings report date is May 08, 2025 which is in 10 days.
How were Eledon Pharmaceuticals, Inc.’s earnings last quarter?
Eledon Pharmaceuticals, Inc. released its earnings results on Mar 20, 2025. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.312 by -$0.328.
Is Eledon Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Eledon Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Eledon Pharmaceuticals, Inc. pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
What is Eledon Pharmaceuticals, Inc.’s EPS estimate?
Eledon Pharmaceuticals, Inc.’s EPS estimate is -0.26.
How many shares outstanding does Eledon Pharmaceuticals, Inc. have?
Eledon Pharmaceuticals, Inc. has 59,881,775 shares outstanding.
What happened to Eledon Pharmaceuticals, Inc.’s price movement after its last earnings report?
Eledon Pharmaceuticals, Inc. reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.312. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ELDN
---
Eledon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.40 (220.99% Upside)
$10.40 (220.99% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.39%
12-Months-Change
Fundamentals
Return on Equity
-93.70%
Trailing 12-Months
Asset Growth
82.25%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
---
ELDN Stock 12 Month Forecast
Average Price Target
$10.40
▲(220.99% Upside)
Technical Analysis
Best Analysts Covering ELDN
1 Year
1 Year Success Rate
9/21 ratings generated profit
1 Year Average Return
+19.68%
reiterated a buy rating last month
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +19.68% per trade.
---